Biomerica's Fortel Kidney Disease Test Approved for Sale in UAE, Enhancing Early Detection of CKD
IRVINE, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- In a significant advancement for public health diagnostics, Biomerica, Inc. (Nasdaq: BMRA), a leading global provider of innovative diagnostic solutions, has announced that its Fortel Kidney Disease (Microalbumin) Test has received approval for sale from the United Arab Emirates (UAE) Ministry of Health and Prevention. This regulatory milestone allows Biomerica to expand its reach into the UAE, a region grappling with a pressing public health crisis due to the high prevalence of chronic kidney disease (CKD).
The Fortel Kidney Disease Test is a state-of-the-art, rapid diagnostic tool that yields accurate results within just ten minutes, using a simple urine sample. This test is pivotal as it detects low levels of microalbumin, a crucial early marker for kidney disease. Individuals suffering from diabetes, hypertension, or obesity, as well as those over the age of 65, are at a notably heightened risk for developing CKD and should undergo routine testing. Globally, CKD poses a significant public health challenge, with more than 80% of at-risk individuals remaining undiagnosed. Furthermore, kidney disease is linked to an increased risk of severe non-communicable diseases, including ischemic heart disease, stroke, and cancer. Projections indicate that by 2040, CKD could become the fifth leading cause of years of life lost worldwide.
Timely detection of CKD is critical, as it enables necessary interventions that can halt or slow the progression toward end-stage renal disease, a condition that often necessitates dialysis or kidney transplantation. Beyond reducing health risks and improving patient quality of life, early diagnosis can also mitigate the significant economic burden associated with advanced kidney disease.
In the UAE, diabetes and hypertension rank among the most significant risk factors contributing to CKD. The International Diabetes Federation reports that over 12% of adults in the UAE currently live with diabetes. Additionally, regional studies suggest that between 29% to 35% of the population suffers from hypertension. Both conditions frequently go undiagnosed until considerable kidney damage has already occurred, leading to CKD being dubbed a silent disease due to its lack of noticeable symptoms until it reaches an advanced and potentially irreversible stage. Consequently, the need for tools such as the Fortel Kidney Disease Test becomes even more pressing.
The Fortel Kidney Disease Test addresses a critical need in preventative healthcare by facilitating the detection of kidney disease before any symptoms present, stated Zack Irani, CEO of Biomerica. Given the high prevalence of diabetes and hypertension in the UAE, this approval aligns perfectly with our mission to deliver life-saving diagnostic solutions to communities that need them the most.
This approval further cements Biomericas growing footprint in the Middle East, following the regional success of its EZ Detect Colon Disease Test and other advanced diagnostic products. The company has strategically partnered with leading distributors and healthcare providers throughout the UAE to ensure that the Fortel Kidney Disease Test is readily available nationwide.
Biomerica is committed to enhancing access to high-quality, cost-effective diagnostic tools that empower both patients and healthcare professionals. The Fortel Kidney Disease Test is part of a broader array of solutions aimed at improving patient outcomes through early detection and personalized healthcare approaches.
About Biomerica (NASDAQ: BMRA): Biomerica, Inc. is a global biomedical technology company that focuses on developing, patenting, manufacturing, and marketing advanced diagnostic and therapeutic products used at the point-of-care, including in-home settings and clinical laboratories. These products are designed to improve health outcomes while simultaneously reducing overall healthcare costs. Biomericas primary areas of focus include gastrointestinal and inflammatory diseases, with numerous diagnostic and therapeutic products in the pipeline.
The Private Securities Litigation Reform Act of 1995 offers a safe harbor for forward-looking statements. Certain information contained in this release, as well as in oral and written statements made by Biomerica, may include forward-looking statements regarding future sales, revenues, expenses, and the efficacy of the Companys products, including the Fortel Kidney Disease Test. These statements involve significant risks and uncertainties that could materially affect future results, including operational earnings, regulatory approvals, market acceptance, and competitive pressures. Biomerica is under no obligation to update any forward-looking statements following the date of this release.
For more information, please contact: Zack Irani | CEO Robert Jackson
Phone: 949.645.2111
Website:
